Small molecule · developed by Novartis Pharmaceuticals
AMO959 (also BY1298, BY101298) is an agent described as a DNA damage response inhibitor. It is being studied in PSMA-positive metastatic castration-resistant prostate cancer in patients who previously received one androgen receptor pathway inhibitor and are candidates for taxane-based chemotherapy.
Summary written with AI from the sources listed at the end of this page.
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →